Aptamer
From Wikipedia, the free encyclopedia
Aptamers are oligonucleic acid or peptide molecules that bind a specific target molecule. Aptamers are usually created by selecting them from a large random sequence pool, but natural aptamers also exist in riboswitches. Aptamers can be used for both basic research and clinical purposes as macromolecular drugs. Aptamers can be combined with ribozymes to self-cleave in the presence of their target molecule. These compound molecules have additional research, industrial and clinical applications.
More specifically, aptamers can be classified as:
- DNA or RNA aptamers. They consist of (usually short) strands of oligonucleotides.
- Peptide aptamers. They consist of a short variable peptide domain, attached at both ends to a protein scaffold.
Contents |
[edit] RNA and DNA aptamers
Aptamers are nucleic acid species that have been evolutionary engineered through in vitro selection or equivalently, SELEX (systematic evolution of ligands by exponential enrichment) to bind to various molecular targets such as small molecules, proteins, nucleic acids, and even cells, tissues and organisms. Aptamers offer the utility for biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of the commonly used biomolecule, antibodies. In addition to their discriminate recognition, aptamers offer advantages over antibodies as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications.
In 1990, two labs independently developed the technique of selection with the Gold lab utilizing the term SELEX for their process of selecting RNA ligands against T4 DNA polymerase and the Szostak lab, coining the term in vitro selection, selecting RNA ligands against various organic dyes. The Szostak lab also coined the term aptamer (from the Latin, aptus, meaning ‘to fit’) for these nucleic acid-based ligands. Two years later, the Szostak lab and Gilead Sciences, independent of one another, utilized in vitro selection schemes to evolve single stranded DNA ligands for organic dyes and human coagulant, thrombin, respectively. There does not appear to be any systematic differences between RNA and DNA aptamers, save the greater intrinsic chemical stability of DNA.
Interestingly enough, the notion of selection in vitro was actually preceded twenty-plus years prior when the infamous Sol Spiegelman utilized a Qbeta replication system as a means for the evolution of a self-replicating molecule. In addition, a year before the publishing of in vitro selection and SELEX, Gerald Joyce utilized a system that he termed ‘directed evolution’ to alter the cleavage activity of a ribozyme.
Over the course of the next sixteen years, many researchers have utilized aptamer selection as a means for application and discovery. In 2001, the process of in vitro selection was automated by the Ellington lab at The University of Texas at Austin, and at SomaLogic, Inc (Boulder, CO), reducing the duration of a selection experiment from six weeks to three days.
While the process of artificial engineering of nucleic acid ligands is highly interesting to biology and biotechnology, the notion of aptamers in the natural world had yet to be uncovered until 2002 when Ronald Breaker and his coworkers discovered a nucleic acid-based genetic regulatory element called a riboswitch that possesses similar molecular recognition properties to the artificially made aptamers. In addition to the discovery of a new mode of genetic regulation, this adds further credence to the notion of an ‘RNA World,’ a postulated stage in time in the origins of life on Earth.
Recent developments in aptamer-based therapeutics have been rewarded in the form of the first FDA approved aptamer-based drug in treatment for age-related macular degeneration (AMD), called Macugen offered by OSI Pharmaceuticals. In addition, companies such as Cambridge, MA-based Archemix have been examining the pharmacological properties of aptamers against targets such as the coagulant thrombin for use in postoperative treatments, complement c5 implicated in inflammatory-related tissue injuries, platelet-derived growth factor that is involved in the diabetic retinopathy disease state, and a few others.
Non-modified aptamers are cleared rapidly from the bloodstream, with a half-life of minutes to hours, mainly due to nuclease degradation and clearance from the body by the kidneys, a result of the aptamer's inherently low molecular weight. Unmodified aptamer applications currently focus on treating transient conditions such as blood clotting, or treating organs such as the eye where local delivery is possible. This rapid clearance can be an advantage in applications such as in vivo diagnostic imaging. An example is a tenascin-binding aptamer under development by Schering AG for cancer imaging. Several modifications, such as 2'-fluorine-substituted pyrimidines, polyethylene glycol (PEG) linkage, etc. (both of which are used in Macugen, an FDA-approved aptamer) are available to scientists with which to increase the half-life of aptamers easily to the day or even week time scale.
In addition to the development of aptamer-based therapeutics, many researchers such as the Ellington lab and the Boulder, CO-based SomaLogic have been developing diagnostic techniques for whole cell protein profiling called proteomics, and medical diagnostics for the distinction of disease versus healthy states.
As a resource for all in vitro selection and SELEX experiments, the Ellington lab has developed the Aptamer Database cataloging all published experiments. This is found at http://aptamer.icmb.utexas.edu/.
[edit] Peptide aptamers
Peptide aptamers are proteins that are designed to interfere with other protein interactions inside cells. They consist of a variable peptide loop attached at both ends to a protein scaffold. This double structural constraint greatly increases the binding affinity of the peptide aptamer to levels comparable to an antibody's (nanomolar range).
The variable loop length is typically comprised of 10 to 20 amino acids, and the scaffold may be any protein which have good solubility and compacity properties. Currently, the bacterial protein Thioredoxin-A is the most used scaffold protein, the variable loop being inserted within the reducing active site, which is a -Cys-Gly-Pro-Cys- loop in the wild protein, the two Cysteins lateral chains being able to form a disulfide bridge.
Peptide aptamer selection can be made using different systems, but the most used is currently the yeast two-hybrid system.
Selection of Ligand Regulated Peptide Aptamers (LiRPAs) has been demonstrated. By displaying 7 amino acid peptides from a novel scaffold protein based on the trimeric FKBP-rapamycin-FRB structure, interaction between the randomized peptide and target molecule can be controlled by the small molecule Rapamycin or non-immunosuppressive analogs.
[edit] References
- Ellington AD, Szostak JW, "In vitro selection of RNA molecules that bind specific ligands.", Nature, 1990 Aug 30;346(6287):818-22. PMID: 1697402
- Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ, "Selection of single-stranded DNA molecules that bind and inhibit human thrombin.", Nature, 1992 Feb 6,355(6360):564-6 PMID: 1741036
- Hoppe-Seyler F, Butz K "Peptide aptamers: powerful new tools for molecular medicine.", J Mol Med. 2000;78(8):426-30.PMID: 11097111
- Carothers JM, Oestreich SC, Davis JH, Szostak JW, "Informational complexity and functional activity of RNA structures.", J Am Chem Soc. 2004 Apr 28;126(16):5130-7. PMID: 15099096
- Cohen BA, Colas P, Brent R, "An artificial cell-cycle inhibitor isolated from a combinatorial library", PNAS 1998 Nov 24;95(24):14272-7. PMID: 9826690
- Binkowski BF, Miller RA, Belshaw PJ, "Ligand Regulated Peptides: A general approach for selection of ligand regulated peptide-protein interactions" Chem & Biol. 2005 July, 12 (7):847-55 PMID: 16039531
- Sullenger BA, Gilboa E, "Emerging clinical applications of RNA" Nature 2002, 418:252-258.
- Ng EW, Shima DT, Calias P, Cunningham ET, Jr., Guyer DR, Adamis AP, "Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease" Nat Rev Drug Discov 2006, 5:123-132.
[edit] Links
Aptamer Database [1]
